RxDoctor Payments Data

Adam Henry, MD

General Practice · Indianapolis, INNPI 1679919294

Payments from drug & device makers

$546in general payments, 2019–2025

Across 31 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$179
  • Amgen$47
  • Novo Nordisk$32
  • Baxter Healthcare$31
  • AstraZeneca$25
  • Pfizer$24
  • plus $207 from 11 others

What the payments were for

  • Food & beverage$50392%
  • Education$122%
  • Other$316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$546 in reported general payments places this provider in the 70th percentile of 1,558 general practice providers in Indiana.

See all general practice providers in Indiana

Medicare billing

Part B allowed, 2024
$17,705
Medicare patients
108
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$119,574
OzempicSemaglutide75$94,181
JardianceEmpagliflozin35$54,433
EliquisApixaban50$48,797
Tresiba Flextouch U-200Insulin Degludec51$36,041
TrulicityDulaglutide21$32,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,983
RybelsusSemaglutide16$24,182
Breo ElliptaFluticasone/Vilanterol38$17,579
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,542
Spiriva RespimatTiotropium Bromide14$7,253
Combivent RespimatIpratropium/Albuterol Sulfate11$5,293
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,124
Atorvastatin Calcium443$4,504
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$22$152,513112 claims
Novo NordiskOzempic, Rybelsus$32$118,36391 claims
PfizerEliquis$24$48,79750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,558 general practice providers in Indiana.

Other general practice in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →